These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

236 related items for PubMed ID: 27582547

  • 1. Detection of CCNE1/URI (19q12) amplification by in situ hybridisation is common in high grade and type II endometrial cancer.
    Noske A, Brandt S, Valtcheva N, Wagner U, Zhong Q, Bellini E, Fink D, Obermann EC, Moch H, Wild PJ.
    Oncotarget; 2017 Feb 28; 8(9):14794-14805. PubMed ID: 27582547
    [Abstract] [Full Text] [Related]

  • 2. Characterization of the 19q12 amplification including CCNE1 and URI in different epithelial ovarian cancer subtypes.
    Noske A, Henricksen LA, LaFleur B, Zimmermann AK, Tubbs A, Singh S, Storz M, Fink D, Moch H.
    Exp Mol Pathol; 2015 Feb 28; 98(1):47-54. PubMed ID: 25527175
    [Abstract] [Full Text] [Related]

  • 3. CCNE1 amplification is associated with aggressive potential in endometrioid endometrial carcinomas.
    Nakayama K, Rahman MT, Rahman M, Nakamura K, Ishikawa M, Katagiri H, Sato E, Ishibashi T, Iida K, Ishikawa N, Kyo S.
    Int J Oncol; 2016 Feb 28; 48(2):506-16. PubMed ID: 26647729
    [Abstract] [Full Text] [Related]

  • 4. Functional characterization of the 19q12 amplicon in grade III breast cancers.
    Natrajan R, Mackay A, Wilkerson PM, Lambros MB, Wetterskog D, Arnedos M, Shiu KK, Geyer FC, Langerød A, Kreike B, Reyal F, Horlings HM, van de Vijver MJ, Palacios J, Weigelt B, Reis-Filho JS.
    Breast Cancer Res; 2012 Mar 20; 14(2):R53. PubMed ID: 22433433
    [Abstract] [Full Text] [Related]

  • 5. Assessment of HER-2/neu, с-MYC and CCNE1 gene copy number variations and protein expression in endometrial carcinomas.
    Buchynska LG, Brieieva OV, Iurchenko NP.
    Exp Oncol; 2019 Jun 20; 41(2):138-143. PubMed ID: 31262163
    [Abstract] [Full Text] [Related]

  • 6. 19q12 amplified and non-amplified subsets of high grade serous ovarian cancer with overexpression of cyclin E1 differ in their molecular drivers and clinical outcomes.
    Aziz D, Etemadmoghadam D, Caldon CE, Au-Yeung G, Deng N, Hutchinson R, Australian Ovarian Cancer Study GroupPeter MacCallum Cancer Centre, Melbourne, Victoria 3000, Australia., Bowtell D, Waring P.
    Gynecol Oncol; 2018 Nov 20; 151(2):327-336. PubMed ID: 30209015
    [Abstract] [Full Text] [Related]

  • 7. Combined CCNE1 high-level amplification and overexpression is associated with unfavourable outcome in tubo-ovarian high-grade serous carcinoma.
    Chan AM, Enwere E, McIntyre JB, Wilson H, Nwaroh C, Wiebe N, Ou Y, Liu S, Wiedemeyer K, Rambau PF, Grevers X, Morris DG, Neri P, Gilks CB, Visser F, Le N, Luo L, Cook LS, Köbel M.
    J Pathol Clin Res; 2020 Oct 20; 6(4):252-262. PubMed ID: 32391646
    [Abstract] [Full Text] [Related]

  • 8. Cyclin E amplification, over-expression, and relapse-free survival in HER-2-positive primary breast cancer.
    Luhtala S, Staff S, Tanner M, Isola J.
    Tumour Biol; 2016 Jul 20; 37(7):9813-23. PubMed ID: 26810187
    [Abstract] [Full Text] [Related]

  • 9. Comprehensive analysis of 19q12 amplicon in human gastric cancers.
    Leung SY, Ho C, Tu IP, Li R, So S, Chu KM, Yuen ST, Chen X.
    Mod Pathol; 2006 Jun 20; 19(6):854-63. PubMed ID: 16575401
    [Abstract] [Full Text] [Related]

  • 10. Amplicon-dependent CCNE1 expression is critical for clonogenic survival after cisplatin treatment and is correlated with 20q11 gain in ovarian cancer.
    Etemadmoghadam D, George J, Cowin PA, Cullinane C, Kansara M, Australian Ovarian Cancer Study Group, Gorringe KL, Smyth GK, Bowtell DD.
    PLoS One; 2010 Nov 12; 5(11):e15498. PubMed ID: 21103391
    [Abstract] [Full Text] [Related]

  • 11. Frequent CCNE1 amplification in endometrial intraepithelial carcinoma and uterine serous carcinoma.
    Kuhn E, Bahadirli-Talbott A, Shih IeM.
    Mod Pathol; 2014 Jul 12; 27(7):1014-9. PubMed ID: 24309323
    [Abstract] [Full Text] [Related]

  • 12. Cyclin E1 (CCNE1) as independent positive prognostic factor in advanced stage serous ovarian cancer patients - a study of the OVCAD consortium.
    Pils D, Bachmayr-Heyda A, Auer K, Svoboda M, Auner V, Hager G, Obermayr E, Reiner A, Reinthaller A, Speiser P, Braicu I, Sehouli J, Lambrechts S, Vergote I, Mahner S, Berger A, Cacsire Castillo-Tong D, Zeillinger R.
    Eur J Cancer; 2014 Jan 12; 50(1):99-110. PubMed ID: 24176298
    [Abstract] [Full Text] [Related]

  • 13. High cyclin E1 protein, but not gene amplification, is prognostic for basal-like breast cancer.
    Aziz D, Lee C, Chin V, Fernandez KJ, Phan Z, kConFab InvestigatorsPeter MacCallum Cancer Centre, Victorian Comprehensive Cancer Centre, Parkville, VIC, Australia.Sir Peter MacCallum Cancer Centre, Department of Oncology, The University of Melbourne, Parkville, VIC, Australia., AOCS Study GroupPeter MacCallum Cancer Centre, Victorian Comprehensive Cancer Centre, Parkville, VIC, Australia., Waring P, Caldon CE.
    J Pathol Clin Res; 2022 Jul 12; 8(4):355-370. PubMed ID: 35384378
    [Abstract] [Full Text] [Related]

  • 14. Histo-genomic stratification reveals the frequent amplification/overexpression of CCNE1 and BRD4 genes in non-BRCAness high grade ovarian carcinoma.
    Goundiam O, Gestraud P, Popova T, De la Motte Rouge T, Fourchotte V, Gentien D, Hupé P, Becette V, Houdayer C, Roman-Roman S, Stern MH, Sastre-Garau X.
    Int J Cancer; 2015 Oct 15; 137(8):1890-900. PubMed ID: 25892415
    [Abstract] [Full Text] [Related]

  • 15. Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer.
    Nakayama N, Nakayama K, Shamima Y, Ishikawa M, Katagiri A, Iida K, Miyazaki K.
    Cancer; 2010 Jun 01; 116(11):2621-34. PubMed ID: 20336784
    [Abstract] [Full Text] [Related]

  • 16. Gene amplification of CCNE1, CCND1, and CDK6 in gastric cancers detected by multiplex ligation-dependent probe amplification and fluorescence in situ hybridization.
    Ooi A, Oyama T, Nakamura R, Tajiri R, Ikeda H, Fushida S, Dobashi Y.
    Hum Pathol; 2017 Mar 01; 61():58-67. PubMed ID: 27864121
    [Abstract] [Full Text] [Related]

  • 17. CCNE1 copy-number gain and overexpression identify ovarian clear cell carcinoma with a poor prognosis.
    Ayhan A, Kuhn E, Wu RC, Ogawa H, Bahadirli-Talbott A, Mao TL, Sugimura H, Shih IM, Wang TL.
    Mod Pathol; 2017 Feb 01; 30(2):297-303. PubMed ID: 27767100
    [Abstract] [Full Text] [Related]

  • 18. Resistance to CDK2 inhibitors is associated with selection of polyploid cells in CCNE1-amplified ovarian cancer.
    Etemadmoghadam D, Au-Yeung G, Wall M, Mitchell C, Kansara M, Loehrer E, Batzios C, George J, Ftouni S, Weir BA, Carter S, Gresshoff I, Mileshkin L, Rischin D, Hahn WC, Waring PM, Getz G, Cullinane C, Campbell LJ, Bowtell DD.
    Clin Cancer Res; 2013 Nov 01; 19(21):5960-71. PubMed ID: 24004674
    [Abstract] [Full Text] [Related]

  • 19. Copy number signatures and CCNE1 amplification reveal the involvement of replication stress in high-grade endometrial tumors oncogenesis.
    Marlin R, Loger JS, Joachim C, Ebring C, Robert-Siegwald G, Pennont S, Rose M, Raguette K, Suez-Panama V, Ulric-Gervaise S, Lusbec S, Bera O, Vallard A, Aline-Fardin A, Colomba E, Jean-Laurent M.
    Cell Oncol (Dordr); 2024 Aug 01; 47(4):1441-1457. PubMed ID: 38564163
    [Abstract] [Full Text] [Related]

  • 20. Cyclin E gene (CCNE) amplification and hCDC4 mutations in endometrial carcinoma.
    Cassia R, Moreno-Bueno G, Rodríguez-Perales S, Hardisson D, Cigudosa JC, Palacios J.
    J Pathol; 2003 Dec 01; 201(4):589-95. PubMed ID: 14648662
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.